STUDI PENGGUNAAN ERITROPOIETIN PADA PASIEN CHRONIC KIDNEY DISEASE DI INSTALASI HEMODIALISA RSUD Dr. ISKAK TULUNGAGUNG

Chronic Kidney Disease (CKD) and end-stage renal disease are progressive and
irreversible renal function disorders where the body fails to maintain metabolism and
fluid and electrolyte balance, leading to uremia, which is the retention of urea and other
nitrogenous wastes in the blood. This study examines the use of erythropoietin in chronic
kidney disease (CKD) patients at the Hemodialysis Unit of Dr. Iskak Hospital,
Tulungagung. The study was conducted retrospectively by analyzing patient medical
records to identify the patterns of erythropoietin administration in CKD patients with
anemia. The data covers the period from January 1 to December 31, 2023, involving 279
CKD patients, of which 75 patients met the inclusion criteria. The study results showed
that erythropoietin was administered 100% twice a week, with a single dose of 3000 IU
in 56% of patients, 2000 IU in 44% of patients, and a combination of 2000 IU and 3000
IU in 100% of patients. Hemoglobin levels increased in 25% of cases, decreased in 20%
of cases, and showed variable changes in other patients. Total Iron Binding Capacity
(TIBC) reached normal levels in 25% of patients, while 75% remained abnormal. These
findings underscore the efficacy of erythropoietin in managing anemia in CKD patients.